Cardiotoxicity of molecularly targeted agents
- PMID: 22758623
- PMCID: PMC3322440
- DOI: 10.2174/157340311799960636
Cardiotoxicity of molecularly targeted agents
Abstract
Cardiac toxicity of molecularly targeted cancer agents is increasingly recognized as a significant side effect of chemotherapy. These new potent therapies may not only affect the survival of cancer cells, but have the potential to adversely impact normal cardiac and vascular function. Unraveling the mechanisms by which these therapies affect the heart and vasculature is crucial for improving drug design and finding alternative therapies to protect patients predisposed to cardiovascular disease. In this review, we summarize the classification and side effects of currently approved molecularly targeted chemotherapeutics.
References
-
- Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction time to recognize a new entity. J Clin Oncol. 2005;23(13 ):2900–2. - PubMed
-
- Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity calling into question the concept of reversibility. J Clin Oncol. 2007;25(23 ):3525–33. - PubMed
-
- Hunter T, Cooper JA. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell. 1981;24:741–52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
